Article
EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors.
Cancer genetics - 1 Aug 2021
Kunimasa Kei, Hirotsu Yosuke, Kukita Yoji, Ueda Yumi, Sato Yoshiharu, Kimura Madoka, Otsuka Tomoyuki, Hamamoto Yuichiro, Tamiya Motohiro, Inoue Takako, Kawamura Takahisa, Nishino Kazumi, Amemiya Kenji, Goto Taichiro, Mochizuki Hitoshi, Honma Keiichiro, Omata Masao, Kumagai Toru
Abstract excerpt
The ALK inhibitors are promising therapeutic agents against lung cancer harboring ALK fusion genes and are currently under development up to the third generation. However, its therapeutic effects are reported to be affected by differences in ALK variants and co-occurrent mutations. Materials and Methods; We experienced an autopsy case of an ALK-positive lung cancer patient who showed primary resistance to three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.